MetaCap

Longeveron (LGVN) vs Theriva Biologics (TOVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Longeveron is the larger company by market cap ($5.6 million vs $5.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LGVN-31.97%TOVX-48.72%
+39%-7%-53%
Oct 7, 20261 yearNov 20, 2026
LGVN-33.06%TOVX-44.70%
+3%-22%-47%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LGVN versus TOVX key metrics
MetricLGVNTOVX
Share price$1.66$0.12
Market cap$5.60M$5.51M
1-day change-8.79%-6.25%
YTD return—-42.86%
1-year return—-45.45%
5-year return—-99.86%
P/E ratio (TTM)—0.10
EPS (TTM)$-7.95$1.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.20M—
Revenue growth (YoY)-49.87%—
Net income (latest FY)$-22.70M$-23.74M
Gross margin66.97%—
Operating margin-1942.20%—
Net margin-1893.58%—
52-week high$12.30$0.49
52-week low$1.31$0.12
Distance from 52-week high-86.50%-75.51%
Analyst consensusnonenone
Avg. price target upside+3589.76%+1983.33%
Average volume115.35K2.02M
Shares outstanding3.23M45.89M
Employees3815
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Longeveron

LGVN stock →

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

About Theriva Biologics

TOVX stock →

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

LGVN vs TOVX FAQ

Which is bigger, Longeveron or Theriva Biologics?

Longeveron (LGVN) is larger, with a market capitalization of $5.60M compared with $5.51M for Theriva Biologics (TOVX).

Are Longeveron and Theriva Biologics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons